Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2013

01-06-2013 | INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Clinical Management of Septic Arthritis

Authors: Katie A. Sharff, Eric P. Richards, John M. Townes

Published in: Current Rheumatology Reports | Issue 6/2013

Login to get access

Abstract

Septic arthritis is a rheumatologic emergency as joint destruction occurs rapidly and can lead to significant morbidity and mortality. Accurate diagnosis can be particularly challenging in patients with underlying inflammatory joint disease. This review outlines the risk factors for septic arthritis and summarizes the causative bacterial organisms. We highlight advances in antibiotic management with a focus on new drugs for methicillin-resistant Staphylococcus aureus (MRSA) and discuss the use of adjunctive therapies for treatment of septic arthritis in adults.
Literature
1.
2.
Geirsson AJ, Statkevicius S, Vikingsson A. Septic arthritis in Iceland 1990–2002: increasing incidence due to iatrogenic infections. Ann Rheum Dis. 2008;67:638–43.PubMedCrossRef
3.
Kaandorp CJ, Van Schaardenburg D, Krijnen P, et al. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum. 1995;38:1819–25.PubMedCrossRef
4.
Kellgren JH, Ball J, Fairbrother RW, et al. Suppurative arthritis complicating rheumatoid arthritis. Br Med J. 1958;1:1193–200.PubMedCrossRef
5.
Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.PubMedCrossRef
6.
Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:1151–7.PubMedCrossRef
7.
Strangfeld A, Listing J. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20:1181–95.PubMedCrossRef
8.
Dolganiuc A, Stavaru C, Anghel M, et al. The migratory and phagocytic activity of polymorphonuclear leukocytes in rheumatoid arthritis and osteoarthritis patients. Roum Arch Microbiol Immunol. 2000;59:43–53.PubMed
9.
Turner RA, Schumacher R, Myers AR. Phagocytic function of polymorphonuclear leukocytes in rheumatic diseases. J Clin Invest. 1973;52:1632–5.PubMedCrossRef
10.
Goldenberg DL. Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum. 1989;32:496–502.PubMedCrossRef
11.
O'Connell PG, Milburn BM, Nashel DJ. Coexistent gout and septic arthritis: a report of two cases and literature review. Clin Exp Rheumatol. 1985;3:265–7.PubMed
12.
Yu KH, Luo SF, Liou LB, et al. Concomitant septic and gouty arthritis--an analysis of 30 cases. Rheumatology (Oxford). 2003;42:1062–6.CrossRef
13.
Hamilton ME, Parris TM, Gibson RS, et al. Simultaneous gout and pyarthrosis. Arch Intern Med. 1980;140:917–9.PubMedCrossRef
14.
• Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:1810–4. A prospective observational study evaluating the risk of septic arthritis in over 4,500 patients with rheumatoid arthritis treated with anti-TNF and non-biological disease-modifying antirheumatic drugs. This study demonstrated that anti-TNF therapy use in RA is associated with doubling the risk of septic arthritis.PubMedCrossRef
15.
Ostensson A, Geborek P. Septic arthritis as a non-surgical complication in rheumatoid arthritis: relation to disease severity and therapy. Br J Rheumatol. 1991;30:35–8.PubMedCrossRef
16.
Albert C, Brocq O, Gerard D, et al. Septic knee arthritis after intra-articular hyaluronate injection. Two case reports. Joint Bone Spine. 2006;73:205–7.PubMedCrossRef
17.
• Smith RM, Schaefer MK, Kainer MA, et al. Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report. N Engl J Med. 2012. A preliminary report on the multistate outbreak of fungal infections associated with injections of methylprednisolone acetate purchased from a single compounding pharmacy.
18.
Ryan MJ, Kavanagh R, Wall PG, et al. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. Br J Rheumatol. 1997;36:370–3.PubMedCrossRef
19.
Gupta MN, Sturrock RD, Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford). 2001;40:24–30.CrossRef
20.
Dubost JJ, Soubrier M, De Champs C, et al. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis. 2002;61:267–9.PubMedCrossRef
21.
Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop. 2006;26:703–8.PubMedCrossRef
22.
Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004;23:701–6.PubMedCrossRef
23.
Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis. 2003;36:429–39.PubMedCrossRef
24.
Lu JJ, Lee SY, Hwa SY, et al. Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2005;43:4156–8.PubMedCrossRef
25.
• Allison DC, Holtom PD, Patzakis MJ, et al. Microbiology of bone and joint infections in injecting drug abusers. Clin Orthop Relat Res. 2010;468:2107–12. A retrospective review describing the microbiology of bone and joint infections in 215 patients with a history of IVDU from the years 1998 to 2005. S. aureus remained the predominant organism with an increased proportion of MRSA infections over the study period.PubMedCrossRef
26.
Weston VC, Jones AC, Bradbury N, et al. Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991. Ann Rheum Dis. 1999;58:214–9.PubMedCrossRef
27.
28.
Schelenz S, Bramham K, Goldsmith D. Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae. Joint Bone Spine. 2007;74:275–8.PubMedCrossRef
29.
O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore). 1983;62:395–406.CrossRef
30.
31.
Kaandorp CJ, Dinant HJ, van de Laar MA, et al. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis. 1997;56:470–5.PubMedCrossRef
32.
Gardner GC, Weisman MH. Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years. Am J Med. 1990;88:503–11.PubMedCrossRef
33.
Newman JH. Review of septic arthritis throughout the antibiotic era. Ann Rheum Dis. 1976;35:198–205.PubMedCrossRef
34.
Mathews CJ, Weston VC, Jones A, et al. Bacterial septic arthritis in adults. Lancet. 2010;375:846–55.PubMedCrossRef
35.
Margaretten ME, Kohlwes J, Moore D, et al. Does this adult patient have septic arthritis? JAMA. 2007;297:1478–88.PubMedCrossRef
36.
Coakley G, Mathews C, Field M, et al. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology (Oxford). 2006;45:1039–41.CrossRef
37.
Gupta MN, Sturrock RD, Field M. Prospective comparative study of patients with culture proven and high suspicion of adult onset septic arthritis. Ann Rheum Dis. 2003;62:327–31.PubMedCrossRef
38.
Fenollar F, Roux V, Stein A, et al. Analysis of 525 samples to determine the usefulness of PCR amplification and sequencing of the 16S rRNA gene for diagnosis of bone and joint infections. J Clin Microbiol. 2006;44:1018–28.PubMedCrossRef
39.
Yang S, Ramachandran P, Hardick A, et al. Rapid PCR-based diagnosis of septic arthritis by early Gram-type classification and pathogen identification. J Clin Microbiol. 2008;46:1386–90.PubMedCrossRef
40.
Stengel D, Bauwens K, Sehouli J, et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis. 2001;1:175–88.PubMedCrossRef
41.
Brancos MA, Peris P, Miro JM, et al. Septic arthritis in heroin addicts. Semin Arthritis Rheum. 1991;21:81–7.PubMedCrossRef
42.
Limbago B, Fosheim GE, Schoonover V, et al. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. J Clin Microbiol. 2009;47:1344–51.PubMedCrossRef
43.
Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290:2976–84.PubMedCrossRef
44.
Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999;340:493–501.PubMedCrossRef
45.
•• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92. Evidence-based guidelines for the management of MRSA infections.PubMedCrossRef
46.
Kutscha-Lissberg F, Hebler U, Muhr G, et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47:3964–6.PubMedCrossRef
47.
Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002;50:747–50.PubMedCrossRef
48.
Moise PA, Forrest A, Birmingham MC, et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother. 2002;50:1017–26.PubMedCrossRef
49.
Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–8.PubMedCrossRef
50.
Manfredi R, Sabbatani S, Chiodo F. Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: a case report and literature review. Scand J Infect Dis. 2005;37:513–7.PubMedCrossRef
51.
Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res. 2004; 67–71.
52.
Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42:66–72.PubMedCrossRef
53.
De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42:1111–7.PubMedCrossRef
54.
Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–83.PubMedCrossRef
55.
Rouse MS, Piper KE, Jacobson M, et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother. 2006;57:301–5.PubMedCrossRef
56.
Forrest GN, Donovan BJ, Lamp KC, et al. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother. 2008;42:213–7.PubMedCrossRef
57.
Lalani T, Boucher HW, Cosgrove SE, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008;61:177–82.PubMedCrossRef
58.
Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42:e108–10.PubMedCrossRef
59.
Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis. 2010;50:737–40.PubMedCrossRef
60.
Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother. 2006;57:578–9.PubMedCrossRef
61.
Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother. 2000;46:775–84.PubMedCrossRef
62.
Chambers HEG, Gilbert D, Moellering R, Saag M. In: Sanford JC, editor. The Sanford Guide to Antimicrobial Therapy. Sperryville, VA: Antimicrobial Therapy, Inc; 2011.
63.
Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2012.
64.
Twilla JD, Gelfand MS, Cleveland KO, et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother. 2011;66:2675–7.PubMedCrossRef
65.
Kaushal R, Hassoun A. Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin. J Antimicrob Chemother. 2012;67:2052–3.PubMedCrossRef
66.
•• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699–709. A metaanalysis of 13 randomized trials comparing outcomes of tigecyline with other control antibiotics demonstrated an increase in mortality and increased noncure rates associated with tigecycline use.PubMedCrossRef
67.
68.
Goldenberg DL, Sexton, D.J. Disseminated Gonococcal Infection. UpToDate; 2012 [updated Novemer 16 2012].
69.
Gerald L, Mandell JEB, Raphael D. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill, Livingstone, Elsevier; 2010.
70.
71.
•• Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of america. Clin Infect Dis. 2013;56:e1–25. Evidence-based and opinion-based recommendations on the management of prosthetic joint infections.PubMedCrossRef
72.
Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537–41.PubMedCrossRef
73.
Ravindran V, Logan I, Bourke BE. Medical vs surgical treatment for the native joint in septic arthritis: a 6-year, single UK academic centre experience. Rheumatology (Oxford). 2009;48:1320–2.CrossRef
74.
Goldenberg DL, Brandt KD, Cohen AS, et al. Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage. Arthritis Rheum. 1975;18:83–90.PubMedCrossRef
75.
Sammer DM, Shin AY. Comparison of arthroscopic and open treatment of septic arthritis of the wrist. J Bone Joint Surg Am. 2009;91:1387–93.PubMedCrossRef
76.
Abdel MP, Perry KI, Morrey ME, et al. Arthroscopic management of native shoulder septic arthritis. J Shoulder Elbow Surg. 2012.
77.
Nusem I, Jabur MK, Playford EG. Arthroscopic treatment of septic arthritis of the hip. Arthroscopy. 2006;22:902 e1–3.
78.
Garcia-Arias M, Balsa A, Mola EM. Septic arthritis. Best Pract Res Clin Rheumatol. 2011;25:407–21.PubMedCrossRef
79.
Butt U, Amissah-Arthur M, Khattak F, et al. What are we doing about septic arthritis? A survey of UK-based rheumatologists and orthopedic surgeons. Clin Rheumatol. 2011;30:707–10.PubMedCrossRef
80.
Sakiniene E, Bremell T, Tarkowski A. Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum. 1996;39:1596–605.PubMedCrossRef
81.
Odio CM, Ramirez T, Arias G, et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J. 2003;22:883–8.PubMedCrossRef
82.
Harel L, Prais D, Bar-On E, et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study. J Pediatr Orthop. 2011;31:211–5.PubMedCrossRef
83.
Wysenbeek AJ, Leitman M, Amit M, et al. Experimental septic arthritis in rabbits treated by a combination of antibiotic and steroid drugs. Clin Exp Rheumatol. 1996;14:507–12.PubMed
84.
Wysenbeek AJ, Volchek J, Amit M, et al. Treatment of staphylococcal septic arthritis in rabbits by systemic antibiotics and intra-articular corticosteroids. Ann Rheum Dis. 1998;57:687–90.PubMedCrossRef
85.
Verdrengh M, Carlsten H, Ohlsson C, et al. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. J Orthop Res. 2007;25:304–10.PubMedCrossRef
86.
87.
Goldenberg DL, Brandt KD, Cathcart ES, et al. Acute arthritis caused by gram-negative bacilli: a clinical characterization. Medicine (Baltimore). 1974;53:197–208.
88.
Kratz A, Greenberg D, Barki Y, et al. Pantoea agglomerans as a cause of septic arthritis after palm tree thorn injury; case report and literature review. Arch Dis Child. 2003;88:542–4.PubMedCrossRef
89.
Freiberg AA, Herzenberg JE, Sangeorzan JA. Thorn synovitis of the knee joint with Nocardia pyarthrosis. Clin Orthop Relat Res. 1993; 233–6.
90.
Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999;340:85–92.PubMedCrossRef
91.
92.
Ohl CA. Infectious Arthritis of Native Joints. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010. p. 1443–56.CrossRef
Metadata
Title
Clinical Management of Septic Arthritis
Authors
Katie A. Sharff
Eric P. Richards
John M. Townes
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0332-4

Other articles of this Issue 6/2013

Current Rheumatology Reports 6/2013 Go to the issue

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Autoantibodies in Polymyositis and Dermatomyositis

INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology

OSTEOARTHRITIS (MB GOLDRING, SECTION EDITOR)

Understanding Developmental Mechanisms in the Context of Osteoarthritis

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Top 10 Things to Know About Lupus Activity Measures

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

The Role of Resistin in Inflammatory Myopathies

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Use of New Oral Anticoagulants in Antiphospholipid Syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits